MedTrace Logo

Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis

NCT02142725 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 468

Last updated 2017-02-09

No results posted yet for this study

Summary

The purpose of this study is to compare two different dosing regimens of phosphatidylcholine versus placebo for the induction of remission in ulcerative colitis patients non-responsive to standard mesalamine treatment.

Conditions

Interventions

DRUG

LT-02

four times per day

DRUG

LT-02

two times per day

DRUG

Placebo

four times per day

Sponsors & Collaborators

  • Dr. Falk Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Axel Dignass, MD · Agaplesion Markus-Krankenhaus, 1st Dept. of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-21
Primary Completion
2016-11-11
Completion
2016-12-16

Countries

  • Germany

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02142725 on ClinicalTrials.gov